GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (FRA:IMU) » Definitions » Research & Development

Immunogen (FRA:IMU) Research & Development : €194.2 Mil (TTM As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is Immunogen Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Immunogen's Research & Development for the three months ended in Sep. 2023 was €44.6 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 was €194.2 Mil.

Immunogen Research & Development Historical Data

The historical data trend for Immunogen's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunogen Research & Development Chart

Immunogen Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 153.35 103.07 94.20 133.74 201.42

Immunogen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.77 55.21 48.21 46.22 44.57

Immunogen Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €194.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunogen  (FRA:IMU) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Immunogen Research & Development Related Terms

Thank you for viewing the detailed overview of Immunogen's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunogen (FRA:IMU) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (FRA:IMU) » Definitions » Research & Development
Comparable Companies
ASND JAZZ PCVX APLS ROIV CYTK CERE UTHR CRSP IONS OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX BNTX ALNY
Traded in Other Exchanges
IMGN:USA IMGN:Mexico
Address
830 Winter Street, Waltham, MA, USA, 02451
Website
https://www.immunogen.com
Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.

Immunogen (FRA:IMU) Headlines

No Headlines